Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

This multicenter phase 1/2 trial investigated the combination of bendamustine, lenalidomide, and dexamethasone in repeating 4-week cycles as treatment for relapsed refractory multiple myeloma (MM). Phase 1 established maximum tolerated dose (MTD). Phase 2 assessed overall response rate at the MTD. S...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2012-05, Vol.119 (20), p.4608-4613
Hauptverfasser: Lentzsch, Suzanne, O'Sullivan, Amy, Kennedy, Ryan C., Abbas, Mohammad, Dai, Lijun, Pregja, Silvana Lalo, Burt, Steve, Boyiadzis, Michael, Roodman, G. David, Mapara, Markus Y., Agha, Mounzer, Waas, John, Shuai, Yongli, Normolle, Daniel, Zonder, Jeffrey A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!